Jens Olsen1, Kenneth Forsstrøm Jensen2, Daniel Sloth Olesen1, Ann Knoop3. 1. Health Economics Department, Incentive, Holte Stationsvej 14, 1st, DK-2840 Holte, Denmark. 2. Pharmaceuticals Division, Roche Denmark, Industriholmen 59, DK-2650 Hvidovre, Denmark. 3. Department of Oncology, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Abstract
AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment. MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages. RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887). CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.
AIM: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment. MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages. RESULTS: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887). CONCLUSION: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.
Entities:
Keywords:
HER2-positive breast cancer; administration; costs
Authors: María Reyes Abad-Sazatornil; Ainhoa Arenaza; Juan Bayo; Jesus García Mata; José María Guinea De Castro; Josefa León; Javier Letellez; Virginia Reguero; Carmen Martínez Chamorro; Antonio Salar Journal: BMC Health Serv Res Date: 2021-04-08 Impact factor: 2.655